PhaseRx, Inc. (PZRXQ)

Market Cap	12.00
Revenue (ttm)	n/a
Net Income (ttm)	-13.89M
Shares Out	11.71M
EPS (ttm)	-1.19
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	140
Average Volume	3,301
Open	0.0000
Previous Close	0.0001
Day's Range	0.0000 - 0.0000
52-Week Range	0.0000 - 0.0001
Beta	34.26
RSI	39.71
Earnings Date	n/a

About PhaseRx

PhaseRx, Inc., a biopharmaceutical company, engages in developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy. The company develops its products based on its proprietary Hybrid mRNA technology platform, which allows the synthesis of missing enzyme inside the cell. Its therapeutic urea cycle disorder programs under development include PRX-OTC to treat ornithine transcarbamylase deficiency; PRX-ASL to treat argininosuccinate lyase deficiency; and PRX-ASS1 t...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 10
• Stock Exchange: OTCMKTS
• Ticker Symbol: PZRXQ